Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors

Circulation Research
André J Scheen

Abstract

Cardiovascular disease (CVD) is a major challenge in the management of type 2 diabetes mellitus. Glucose-lowering agents that reduce the risk of major cardiovascular events would be considered a major advance, as recently reported with liraglutide and semaglutide, 2 glucagon-like peptide-1 receptor agonists, and with empagliflozin and canagliflozin, 2 SGLT-2 (sodium-glucose cotransporter type 2) inhibitors, but not with DPP-4 (dipeptidyl peptidase-4) inhibitors. The present review is devoted to CV effects of new oral glucose-lowering agents. DPP-4 inhibitors (gliptins) showed some positive cardiac and vascular effects in preliminary studies, and initial data from phase 2 to 3 clinical trials suggested a reduction in major cardiovascular events. However, subsequent CV outcome trials with alogliptin, saxagliptin, and sitagliptin showed noninferiority but failed to demonstrate any superiority compared with placebo in patients with type 2 diabetes mellitus and high CV risk. An unexpected higher risk of hospitalization for heart failure was reported with saxagliptin. SGLT-2 inhibitors (gliflozins) promote glucosuria, thus reducing glucose toxicity and body weight, and enhance natriuresis, thus lowering blood pressure. Two CV outcome...Continue Reading

References

Sep 12, 2008·The New England Journal of Medicine·Allison B Goldfine
Aug 6, 2009·Diabetologia·UNKNOWN Control GroupM Woodward
Mar 4, 2011·The New England Journal of Medicine·Sreenivasa Rao Kondapally SeshasaiUNKNOWN Emerging Risk Factors Collaboration
May 25, 2011·Endocrine Reviews·Muhammad A Abdul-GhaniRalph A Defronzo
Feb 11, 2012·Endocrine Reviews·John R Ussher, Daniel J Drucker
Jul 4, 2012·Lancet·André J Scheen, Nicolas Paquot
Jan 5, 2013·Cardiovascular Diabetology·Samuel S EngelBarry J Goldstein
Jan 9, 2013·Nature Reviews. Cardiology·André J Scheen
Mar 2, 2013·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Julio RosenstockHans-Jürgen Woerle
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Mar 14, 2014·The Lancet. Diabetes & Endocrinology·André J Scheen
Apr 18, 2014·The New England Journal of Medicine·Edward W GreggLinda Geiss
May 24, 2014·Circulation Research·John R Ussher, Daniel J Drucker
Sep 13, 2014·Endocrine Reviews·Erin E Mulvihill, Daniel J Drucker
Oct 7, 2014·Current Treatment Options in Cardiovascular Medicine·Eberhard StandlOliver Schnell
Nov 11, 2014·Expert Opinion on Pharmacotherapy·André J Scheen
Jan 16, 2015·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Silvio E InzucchiOdd Erik Johansen
Jan 30, 2015·Expert Opinion on Drug Safety·André J Scheen
Feb 26, 2015·Diabetes, Obesity & Metabolism·A S AbdelmoneimS H Simpson
Mar 12, 2015·Diabetes Care·Lawrence A LeiterUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Mar 18, 2015·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Nikolaus MarxHans-Juergen Woerle
Jun 9, 2015·The New England Journal of Medicine·Jennifer B GreenUNKNOWN TECOS Study Group
Jun 13, 2015·European Heart Journal·Ele Ferrannini, Ralph A DeFronzo
Jun 19, 2015·The Journal of Clinical Endocrinology and Metabolism·Simeon I TaylorKristina I Rother
Jun 26, 2015·Naunyn-Schmiedeberg's Archives of Pharmacology·Martin C MichelVolker Vallon
Jul 17, 2015·Diabetes Care·Giulia FerranniniEle Ferrannini
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Oct 30, 2015·Expert Opinion on Drug Safety·André J Scheen
Nov 3, 2015·The American Journal of Medicine·Matthew A CavenderDeepak L Bhatt

❮ Previous
Next ❯

Citations

Feb 1, 2019·Diabetic Medicine : a Journal of the British Diabetic Association·D StoyanovaUNKNOWN DPV Initiative
Mar 8, 2019·Diabetes, Obesity & Metabolism·Rosalie A ScholtesDaniël H van Raalte
Apr 24, 2019·International Journal of Molecular Sciences·Simona MarchiselloAgata Maria Rabuazzo
Jun 1, 2019·Expert Opinion on Drug Safety·Elizabeth Mary LamosStephen N Davis
Jan 9, 2020·Preparative Biochemistry & Biotechnology·C PrasannarajaKrishnan Venkataraman
Apr 3, 2020·Journal of Clinical Medicine·José Luis GórrizJuan José Gorgojo-Martinez
May 22, 2020·Circulation Research·Rebecca H Ritchie, E Dale Abel
Jun 4, 2020·The American Journal of Clinical Nutrition·Ronald M Krauss, Penny M Kris-Etherton
Feb 23, 2019·Arteriosclerosis, Thrombosis, and Vascular Biology·Ann Marie Schmidt
Jun 8, 2018·Circulation Journal : Official Journal of the Japanese Circulation Society·Takahiro Okumura, Toyoaki Murohara
May 21, 2020·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Alexander E Berezin, Alexander A Berezin
Sep 29, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Luciana Neves Cosenso-MartinJose Fernando Vilela-Martin
Jul 14, 2018·Diabetes, Obesity & Metabolism·Emanuel RaschiFabrizio De Ponti
Oct 10, 2018·Expert Opinion on Pharmacotherapy·Emanuel RaschiGiulio Marchesini
Aug 3, 2018·Expert Opinion on Drug Safety·André J Scheen
Aug 16, 2018·Journal of Nuclear Cardiology : Official Publication of the American Society of Nuclear Cardiology·Kuan-Yin KoYen-Wen Wu
Jan 4, 2019·Circulation Research·Helena C Kenny, E Dale Abel
Mar 2, 2019·Cardiovascular Diabetology·Atsushi Tanaka, Koichi Node
Apr 2, 2019·Expert Opinion on Drug Safety·André J Scheen
Nov 19, 2019·Biotechnology and Applied Biochemistry·Ill-Min ChungMuthu Thiruvengadam
Aug 28, 2020·Frontiers in Pharmacology·Inés ValenciaTania Romacho
Jul 16, 2020·Nature Reviews. Cardiology·Martin R Cowie, Miles Fisher
Feb 13, 2019·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Pantelis SarafidisMads Hornum
Jan 7, 2020·Journal of the American Heart Association·Valeria RaparelliLouise Pilote
Aug 12, 2020·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Charalampos I LiakosJohn D Barbetseas
Nov 27, 2018·Expert Opinion on Drug Metabolism & Toxicology·Mattia GalliNadia Aspromonte
Nov 27, 2020·Zeitschrift für Gerontologie und Geriatrie·Andrej ZeyfangHans Jürgen Heppner

❮ Previous
Next ❯

Methods Mentioned

BETA
amputations
amputation

Clinical Trials Mentioned

NCT01897532
NCT01243424
NCT01730534

Software Mentioned

CANVAS
EMPA
R
CVD
DECLARE
REG
EXAMINE
TECOS
CARMELINA
CAROLINA

Related Concepts

Related Feeds

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Related Papers

Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy
Tricia Santos Cavaiola, Jeremy Pettus
Advances in Chronic Kidney Disease
Lisanne C de VosMark E Cooper
© 2022 Meta ULC. All rights reserved